Alzheimer’s and Dementia

The Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study will assess the impact of amyloid positron emission tomography (PET) imaging on outcomes in patients with mild cognitive impairment or dementia of uncertain origin. Researchers seek to demonstrate that amyloid PET can help clinicians diagnose the cause of cognitive impairment, provide the most appropriate treatments and recommendations, and improve health outcomes.

Constantine Gatsonis Ani Eloyan

The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) is the largest observational study designed to understand the progression of early-onset Alzheimer's disease (AD) and investigate and identify cognitive, imaging, and genetic biomarkers of disease progression for use in clinical trials. The study is recruiting cognitively normal volunteers as well as people with early-onset nonAD dementias for comparison, while similarities and differences from late-onset AD are investigated using a subset from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. One of the major goals of the study is to collect and publicly share a large database of imaging, cognitive, and genetic data to facilitate future research in early-onset AD biomarker development.

Ani Eloyan Constantine Gatsonis

Delirium, Dementia,and the Vulnerable Brain: An Integrated Approach (Project 4: Defining Phenotype of Complicated Delirium) This project will identify and validate predictors of complicated delirium, i.e., delirium associated with long-term cognitive decline. All of these studies will utilize both the original SAGES I cohort, and a new prospectively enrolled cohort, SAGES II (N=400), which will include CSF sampling obtained prior to spinal anesthesia.

Jon Steingrimsson